Published in Clin Colorectal Cancer on March 01, 2011
Colorectal cancer screening--optimizing current strategies and new directions. Nat Rev Clin Oncol (2013) 1.35
Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer (2013) 1.21
Colorectal cancer. Nat Rev Dis Prim (2015) 1.07
The expression of microRNA-375 in plasma and tissue is matched in human colorectal cancer. BMC Cancer (2014) 1.02
DNA testing and molecular screening for colon cancer. Clin Gastroenterol Hepatol (2013) 0.98
New strategies for colorectal cancer screening. World J Gastroenterol (2013) 0.95
Molecular markers for colorectal cancer screening. Gut (2015) 0.92
Genetic and epigenetic traits as biomarkers in colorectal cancer. Int J Mol Sci (2011) 0.90
Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. World J Gastroenterol (2016) 0.87
LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy. PLoS One (2015) 0.83
Accuracy of early detection of colorectal tumours by stool methylation markers: a meta-analysis. World J Gastroenterol (2014) 0.82
Detection of promoter hypermethylation of Wnt antagonist genes in fecal samples for diagnosis of early colorectal cancer. World J Gastroenterol (2014) 0.82
Current and future molecular diagnostics in colorectal cancer and colorectal adenoma. World J Gastroenterol (2014) 0.82
Evaluation of specific fecal protein biochips for the diagnosis of colorectal cancer. World J Gastroenterol (2014) 0.79
Surveillance after curative treatment for colorectal cancer. Nat Rev Clin Oncol (2016) 0.75
CTNNB1-mutant colorectal carcinomas with immediate invasive growth: a model of interval cancers in Lynch syndrome. Fam Cancer (2016) 0.75
Early detection: the impact of genomics. Virchows Arch (2017) 0.75
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet (2002) 5.38
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol (2008) 5.21
Resolving the resolution of array CGH. Genomics (2007) 3.66
Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer (2003) 3.47
Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet (2007) 3.39
BAC to the future! or oligonucleotides: a perspective for micro array comparative genomic hybridization (array CGH). Nucleic Acids Res (2006) 3.32
Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology (2008) 3.18
Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res (2008) 3.06
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res (2002) 2.86
Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. Nat Genet (2005) 2.71
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer (2007) 2.68
Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J Clin Invest (2003) 2.66
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol (2002) 2.55
GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol (2003) 2.42
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol (2006) 2.33
N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst (2009) 2.22
PPIB mutations cause severe osteogenesis imperfecta. Am J Hum Genet (2009) 2.16
VHL and HIF signalling in renal cell carcinogenesis. J Pathol (2010) 2.13
Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Cancer Res (2011) 2.06
Human and mouse oligonucleotide-based array CGH. Nucleic Acids Res (2005) 2.03
Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. J Clin Oncol (2007) 1.97
Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). Drug Resist Updat (2002) 1.91
Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol (2010) 1.90
Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. J Clin Oncol (2013) 1.89
Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. Mol Imaging Biol (2003) 1.86
Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res (2009) 1.80
GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin Cancer Res (2009) 1.78
On the beta-binomial model for analysis of spectral count data in label-free tandem mass spectrometry-based proteomics. Bioinformatics (2009) 1.74
Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer (2010) 1.69
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res (2008) 1.69
The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications. FASEB J (2010) 1.68
Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut (2010) 1.68
Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol (2010) 1.60
Genetics and epigenetics of renal cell cancer. Biochim Biophys Acta (2007) 1.56
Proteomics analysis of rat brain postsynaptic density. Implications of the diverse protein functional groups for the integration of synaptic physiology. J Biol Chem (2003) 1.56
Higher fecal immunochemical test cutoff levels: lower positivity rates but still acceptable detection rates for early-stage colorectal cancers. Cancer Epidemiol Biomarkers Prev (2010) 1.55
Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J Immunol (2002) 1.52
Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther (2002) 1.52
Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol (2002) 1.49
Colorectal cancer epigenetics: complex simplicity. J Clin Oncol (2011) 1.47
Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival. Cell Oncol (2004) 1.46
Smoothing waves in array CGH tumor profiles. Bioinformatics (2009) 1.45
Methylation-specific PCR unraveled. Cell Oncol (2004) 1.44
Risk of colorectal cancer in patients with Barrett's esophagus: A Dutch population-based study. Am J Gastroenterol (2009) 1.44
The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim Biophys Acta (2011) 1.43
Macrophages direct tumour histology and clinical outcome in a colon cancer model. J Pathol (2005) 1.40
Genomic profiling of gastric cancer predicts lymph node status and survival. Oncogene (2003) 1.40
Lamin A/C is a risk biomarker in colorectal cancer. PLoS One (2008) 1.37
Body size and risk for colorectal cancers showing BRAF mutations or microsatellite instability: a pooled analysis. Int J Epidemiol (2012) 1.33
Analysis of promoter CpG island hypermethylation in cancer: location, location, location! Clin Cancer Res (2011) 1.33
Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP). PLoS One (2011) 1.32
Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. J Pathol (2012) 1.30
Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res (2002) 1.30
A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer. Clin Cancer Res (2011) 1.28
Endoscopic trimodal imaging versus standard video endoscopy for detection of early Barrett's neoplasia: a multicenter, randomized, crossover study in general practice. Gastrointest Endosc (2010) 1.27
Integrated genomic and transcriptional profiling identifies chromosomal loci with altered gene expression in cervical cancer. Genes Chromosomes Cancer (2008) 1.26
Retracted Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. Mult Scler Int (2011) 1.26
Across array comparative genomic hybridization: a strategy to reduce reference channel hybridizations. Genes Chromosomes Cancer (2008) 1.25
CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype. Carcinogenesis (2005) 1.23
Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas. Cancer Prev Res (Phila) (2011) 1.23
Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.22
Rapid quantification of myocardial fibrosis: a new macro-based automated analysis. Cell Oncol (Dordr) (2011) 1.22
Determination of amplicon boundaries at 20q13.2 in tissue samples of human gastric adenocarcinomas by high-resolution microarray comparative genomic hybridization. J Pathol (2003) 1.21
Early life exposure to famine and colorectal cancer risk: a role for epigenetic mechanisms. PLoS One (2009) 1.21
MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors. Blood (2002) 1.21
Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D1 and hypoxia-inducible factor-1alpha (HIF-1alpha). Oncogene (2003) 1.20
The CpG island methylator phenotype: what's in a name? Cancer Res (2013) 1.20
Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res (2007) 1.20
Does delay in diagnosing colorectal cancer in symptomatic patients affect tumor stage and survival? A population-based observational study. BMC Cancer (2010) 1.20
Body size and colorectal cancer risk after 16.3 years of follow-up: an analysis from the Netherlands Cohort Study. Am J Epidemiol (2011) 1.20
KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA. J Mol Diagn (2012) 1.19
Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother (2008) 1.18
Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res (2002) 1.18
Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression. Tumour Biol (2010) 1.16
Subnuclear proteomics in colorectal cancer: identification of proteins enriched in the nuclear matrix fraction and regulation in adenoma to carcinoma progression. Mol Cell Proteomics (2010) 1.16
Stromal expression of hypoxia regulated proteins is an adverse prognostic factor in colorectal carcinomas. Cell Oncol (2007) 1.16
Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic antigen on colorectal cancer cells through dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin. Cancer Res (2005) 1.16
TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression. Gut (2011) 1.15
Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan. Gastroenterology (2011) 1.15
The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma. Cancer Immunol Immunother (2006) 1.14
iTRAQ-based proteomics profiling reveals increased metabolic activity and cellular cross-talk in angiogenic compared with invasive glioblastoma phenotype. Mol Cell Proteomics (2009) 1.14